Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

Alan K Davis, Lynnette A Averill, Nathan D Sepeda, Joseph P Barsuglia, Timothy Amoroso, Alan K Davis, Lynnette A Averill, Nathan D Sepeda, Joseph P Barsuglia, Timothy Amoroso

Abstract

Background: U.S. Special Operations Forces Veterans are at increased risk for a variety of mental health problems and cognitive impairment associated with military service. Current treatments are lacking in effectiveness and adherence. Therefore, this study examined psychedelic treatment with ibogaine and 5-methoxy-N,N-dimethyltryptamine for trauma-related psychological and cognitive impairment among U.S. Special Operations Forces Veterans.

Method: We conducted a survey of Veterans who completed a specific psychedelic clinical program in Mexico between 2017 and 2019. Questions probed retrospective reports of mental health and cognitive functioning during the 30 days before and 30 days after treatment. A total of 65 people completed treatment during this time frame and were eligible for contact. Of these, 51 (78%) completed the survey and were included in data analyses (mean age = 40; male = 96%; married = 55%; Caucasian/White = 92%; Operation Enduring Freedom/Operation Iraqi Freedom Service = 96%).

Results: Results indicated significant and very large reductions in retrospective report of suicidal ideation (p < .001; d = -1.9), cognitive impairment (p < .001; d = -2.8), and symptoms of posttraumatic stress disorder (p < .001; d = -3.6), depression (p < .001; d = -3.7), and anxiety (p < .001; d = -3.1). Results also showed a significant and large increase in retrospective report of psychological flexibility (p < .001; d = 2.9) from before-to-after the psychedelic treatment. Increases in the retrospective report of psychological flexibility were strongly associated with retrospective report of reductions in cognitive impairment, and symptoms of posttraumatic stress disorder, depression, and anxiety (rs range -0.61 to -0.75; p < .001). Additionally, most participants rated the psychedelic experiences as one of the top five personally meaningful (84%), spiritually significant (88%), and psychologically insightful (86%) experiences of their lives.Limitations: Several limitations should be considered including the retrospective, self-report, survey design of the study, and the lack of randomization and blinding, thus making these finding preliminary.

Conclusion: U.S. Special Operations Forces Veterans may have unique treatment needs because of the sequela of problems associated with repeated trauma exposure and the nature of the exposure. Psychedelic-assisted therapy with these under-researched psychedelics may hold unique promise for this population. However, controlled studies are needed to determine whether this treatment is efficacious in relieving mental health and cognitive impairment among U.S. Special Operations Forces Veterans.

Keywords: 5-methoxy-N,N-dimethyltryptamine; cognitive impairment; ibogaine; special operations; trauma; veterans.

© The Author(s) 2020.

References

    1. Bartone PT, Roland RR, Picano JJ.Williams TJ. Psychological hardiness predicts success in US Army Special Forces candidates. Int J Sel Assess. 2008; 16: 78–81.
    1. Hanwella R, de Silva V. Mental health of Special Forces personnel deployed in battle. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 1343–1351.
    1. Hing M, Cabrera J, Barstow C.Forsten R. Special Operations Forces and incidence of post-traumatic stress disorder symptoms. J Spec Oper Med Peer Rev J SOF Med Prof. 2012; 12: 23–35.
    1. Rocklein Kemplin K, Paun O, Godbee DC.Brandon JW. Resilience and suicide in Special Operations Forces: state of the science via integrative review. J Spec Oper Med Peer Rev J SOF Med Prof. 2019; 19: 57–66.
    1. Greer N, Sayer NA, Spoont M, et al. Prevalence and severity of psychiatric disorders and suicidal behavior in service members and veterans with and without traumatic brain injury: systematic review. J Head Trauma Rehabil. 2020; 35: 1–13.
    1. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013; 74: e541–e550.
    1. Steenkamp MM, Litz BT, Hoge CW.Marmar CR. Psychotherapy for military-related PTSD: a review of randomized clinical trials. J Am Med Assoc. 2015; 314: 489.
    1. Bisson JI, Ehlers A, Matthews R.Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2007; 190: 97–104.
    1. Puetz TW, Youngstedt SD, Herring MP. Effects of pharmacotherapy on combat-related PTSD, anxiety, and depression: a systematic review and meta-regression analysis. PLoS One. 2015; 10: e0126529.
    1. Lee DJ, Schnitzlein CW, Wolf JP.Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016; 33: 792–806.
    1. Friedman MJ, Marmar CR, Baker DG.Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry. 2007; 68: 711–720.
    1. Gutner CA, Galovski T, Bovin MJ.Schnurr PP. Emergence of transdiagnostic treatments for PTSD and posttraumatic distress. Curr Psychiatry Rep. 2016; 18: 95.
    1. Varkovitzky RL, Sherrill AM, Reger GM. Effectiveness of the unified protocol for transdiagnostic treatment of emotional disorders among veterans with posttraumatic stress disorder: a pilot study. Behav Modif. 2018; 42: 210–230.
    1. dos Santos RG, Bouso JC, Hallak JEC. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC Psychiatry. 2019; 19: 321.
    1. Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017; 42: 2114–2127.
    1. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl ). 2018; 235: 399–408.
    1. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 64: 250–258.
    1. Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Curr Top Behav Neurosci. 2018; 36: 361–391.
    1. Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016; 3: 481–488.
    1. Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018; 5: 486–497.
    1. Barrett FS, Doss MK, Sepeda ND.Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020; 10: 2214.
    1. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol (Oxf). 2011; 25: 1453–1461.
    1. Wagner MT, Mithoefer MC, Mithoefer AT, et al. Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol Oxf Engl. 2017; 31: 967–974.
    1. Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013; 6: 3–16.
    1. Wasko MJ, Witt-Enderby PA, Surratt CK. DARK classics in chemical neuroscience: ibogaine. ACS Chem Neurosci. 2018; 9: 2475–2483.
    1. Davis AK, Barsuglia JP, Windham-Herman A-M.Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017; 1: 65–73.
    1. Mash DC, Duque L, Page B.Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Front Pharmacol. 2018; 9: 529.
    1. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018; 44: 37–46.
    1. Barsuglia JP, Polanco M, Palmer R.Malcolm BJ, Kelmendi B, Calvey TA. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res. 2018; 242: 121–158.
    1. Schenberg EE, de Castro Comis MA, Alexandre JFM.Chaves BDR, Tófoli LF, da Silveira DX. Treating drug dependence with the aid of ibogaine: a qualitative study. J Psychedelic Stud. 2017; 1: 10–19.
    1. Schenberg EE, de Castro Comis MA, Alexandre JFM.Tófoli LF, Chaves BDR, da Silveira DX. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. J Psychedelic Stud. 2017; 1: 74–83.
    1. Winkelman M. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Curr Drug Abuse Rev. 2014; 7: 101–116.
    1. Bulling S, Schicker K, Zhang Y-W, et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem. 2012; 287: 18524–18534.
    1. Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 1997; 749: 340–343.
    1. He D-Y, McGough NNH, Ravindranathan A, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci Off J Soc Neurosci. 2005; 25: 619–628.
    1. Marton S, González B, Rodríguez-Bottero S, et al. Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Front Pharmacol. 2019; 10: 193.
    1. Bolshakova AV, Kukanova EO, Gainullina AN.Zhemkov VA, Korban SA, Bezprozvanny IB. Sigma-1 receptor as a potential pharmacological target for the treatment of neuropathology. St Petersburg Polytech Univ J Phys Math. 2016; 2: 31–40.
    1. Collingridge GL, Volianskis A, Bannister N, et al. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013; 64: 13–26.
    1. Kim H, Oh M, Oh JS, et al. Association of striatal dopaminergic neuronal integrity with cognitive dysfunction and cerebral cortical metabolism in Parkinson’s disease with mild cognitive impairment. Nucl Med Commun. 2019; 40: 1216–1223.
    1. Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des. 2012; 18: 875–883.
    1. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011; 10: 209–219.
    1. Singewald N, Schmuckermair C, Whittle N.Holmes A, Ressler KJ. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther. 2015; 149: 150–190.
    1. Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Mol Basel Switz. 2015; 20: 2208–2228.
    1. Corkery JM. Chapter 8 - Ibogaine as a treatment for substance misuse: potential benefits and practical dangers In: Calvey T, ed. Progress in Brain Research. Amsterdam: Elsevier; 2018: 217–257.
    1. Brown TK, Noller GE, Denenberg JO. Ibogaine and subjective experience: transformative states and psychopharmacotherapy in the treatment of opioid use disorder. J Psychoactive Drugs. 2019; 51: 155–165.
    1. Ott J. Pharmepéna-Psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. J Psychoactive Drugs. 2001; 33: 403–407.
    1. Weil AT, Davis W. Bufo alvarius: a potent hallucinogen of animal origin. J Ethnopharmacol. 1994; 41: 1–8.
    1. Davis AK, So S, Lancelotta R.Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019; 45: 161–169.
    1. Cox K, Lancelotta RL, Barsuglia J.Davis AK. 5-MeO-DMT and subjective improvements in post-traumatic stress disorder. Published 2018. Accessed May 1, 2020.
    1. Davis AK, Barsuglia JP, Lancelotta R.Grant RM, Elise R. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol Oxf Engl. 2018; 32: 779–792.
    1. Uthaug MV, Lancelotta R, van Oorsouw K, et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology (Berl ). 2019; 236: 2653–2666.
    1. Barsuglia J, Davis AK, Palmer R, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol. 2018; 9: 2459.
    1. Griffiths RR, Johnson MW, Richards WA.Richards BD, McCann U, Robert J. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl ). 2011; 218: 649–665.
    1. Griffiths RR, Hurwitz ES, Davis AK.Johnson MW, Robert J. Survey of subjective ‘God encounter experiences’: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One. 2019; 14: e0214377.
    1. Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology (Berl ). 2018; 235: 535–545.
    1. Lima da Cruz RV, Moulin TC, Petiz LL.Leão RN. A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Front Mol Neurosci. 2018; 11: 312.
    1. Dakic V, Minardi Nascimento J, Costa Sartore R, et al. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci Rep. 2017; 7: 12863.
    1. Szabo A, Kovacs A, Frecska E.Rajnavolgyi E, Langmann T. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One. 2014; 9: e106533.
    1. Dabire H, Cherqui C, Fournier B.Schmitt H. Comparison of effects of some 5-HT1 agonists on blood pressure and heart rate of normotensive anaesthetized rats. Eur J Pharmacol. 1987; 140: 259–266.
    1. Barsuglia J, Davis AK, Palmer R, et al. Characterization of mystical experiences occasioned by 5-MeO-DMT-containing toad bufotoxin and comparison with prior psilocybin studies. Published 2017. Accessed June 19, 2019.
    1. Erowid. The Sonoran Desert toad. Published 2017. Accessed May 29, 2020.
    1. Blevins CA, Weathers FW, Davis MT.Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015; 28: 489–498.
    1. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003; 41: 1284–1292.
    1. Kroenke K, Spitzer RL, Williams JBW.Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146: 317–325.
    1. Plummer F, Manea L, Trepel D.McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016; 39: 24–31.
    1. Joiner TE, Pfaff JJ, Acres JG. A brief screening tool for suicidal symptoms in adolescents and young adults in general health settings: reliability and validity data from the Australian National General Practice Youth Suicide Prevention Project. Behav Res Ther. 2002; 40: 471–481.
    1. von Glischinski M, Teismann T, Prinz S.Gebauer JE, Hirschfeld G. Depressive Symptom Inventory Suicidality Subscale: optimal cut points for clinical and non-clinical samples. Clin Psychol Psychother. 2016; 23: 543–549.
    1. Hays RD, Sherbourne CD, Mazel R. User’s Manual for the Medical Outcomes Study (MOS) Core Measures of Health-Related Quality of Life. Santa Monica, CA: RAND Corporation; 1995.
    1. Bond FW, Hayes SC, Baer RA, et al. Preliminary psychometric properties of the Acceptance and Action Questionnaire–II: a revised measure of psychological inflexibility and experiential avoidance. Behav Ther. 2011; 42: 676–688.
    1. Department of Veterans Affairs. National Survey of Veterans, Active Duty Service Members, Demobilized National Guard and Reserve Members, Family Members, and Surviving Spouses. Washington, DC: Department of Veterans Affairs; 2010.
    1. IBM Corp. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp; 2018.
    1. Krystal JH, Davis LL, Neylan TC, et al. It is time to address the crisis in the pharmacotherapy of posttraumatic stress disorder: a consensus statement of the PTSD psychopharmacology working group. Biol Psychiatry. 2017; 82: e51–e59.
    1. Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Context Behav Sci. 2020; 15: 39–45.
    1. Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Context Behav Sci. 2020; 15: 92–102.
    1. Ben-Zion Z, Fine NB, Keynan NJ, et al. Cognitive flexibility predicts PTSD symptoms: observational and interventional studies. Front Psychiatry. 2018; 9: 477.
    1. Keith J, Velezmoro R, O’Brien C. . Correlates of cognitive flexibility in veterans seeking treatment for posttraumatic stress disorder. J Nerv Ment Dis. 2015; 203: 287–293.
    1. Nutt DJ, King LA, Nichols DE. Effects of schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013; 14: 577–585.
    1. Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015; 18: 110–115.
    1. Nolte S, Elsworth GR, Sinclair AJ.Osborne RH. The inclusion of ‘then-test’ questions in post-test questionnaires alters post-test responses: a randomized study of bias in health program evaluation. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2012; 21: 487–494.
    1. Bomyea J, Lang AJ. Emerging interventions for PTSD: future directions for clinical care and research. Neuropharmacology. 2012; 62: 607–616.
    1. Murphy D, Smith KV. Treatment efficacy for veterans with posttraumatic stress disorder: latent class trajectories of treatment response and their predictors. J Trauma Stress. 2018; 31: 753–763.
    1. Cheney AM, Koenig CJ, Miller CJ, et al. Veteran-centered barriers to VA mental healthcare services use. BMC Health Serv Res. 2018; 18: 591.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever